Acquisitions, Upcoming Earnings, Presentation Schedules, and Annual Stockholder Meetings - Research Report on Baxter, Varian Medical Systems, ResMed, Wright Medical Group and Chemed
NEW YORK, December 10, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE:BAX), Varian Medical Systems Inc. (NYSE: VAR), ResMed Inc. (NYSE: RMD), Wright Medical Group Inc. (NASDAQ: WMGI) and Chemed Corp. (NYSE: CHE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Baxter International Inc. Research Report
On December 2, 2013, Baxter International Inc. (Baxter) and Halozyme Therapeutics, Inc. (Halozyme) jointly announced that Baxter has completed submission of an amended biologics license application (BLA) to the United States Food and Drug Administration (FDA) to re-initiate the review process for approval of HyQvia [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] facilitated subcutaneous infusion for the treatment of adult patients with primary immunodeficiency (PI). According to the Company, HyQvia is a combination of human immune globulin (IG) and recombinant human hyaluronidase. Baxter reported that the two Companies submitted additional preclinical data that was requested from the FDA in 2012, and expect a six-month review period. "We believe that if approved, HyQvia may become a valuable option for patients with immune deficiency as it allows for the delivery of a full dose of immunoglobulin often in a single site every three to four weeks, in the comfort of a patient's home," said Ludwig Hantson, Ph.D., President of Baxter's BioScience business. According to Baxter, HyQvia was approved and launched in a number of European countries in H2 2013. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/163d_BAX
--
Varian Medical Systems Inc. Research Report
On December 3, 2013, Varian Medical Systems Inc. (Varian Medical Systems) announced that its Board of Directors is scheduled to conduct the 2014 Annual Meeting of Stockholders with a record date of December 23, 2013, on February 20, 2014 at 4:30 p.m. PT. According to the Company, the aforesaid meeting will be held at the Company's headquarters located at 3100 Hansen Way, Palo Alto, CA 94304. The Company informed that interested parties can access a webcast of the meeting at Varian Medical Systems' website. The Full Research Report on Varian Medical Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/bd48_VAR
--
ResMed Inc. Research Report
On December 2, 2013, ResMed Inc. (ResMed) reported that it has acquired Prague-based Unimedis, a distributor of equipment for the treatment of sleep disordered-breathing in the Czech Republic and Slovakia. ResMed-Europe President, Anne Reiser commented, "The Czech and Slovak markets have tremendous growth opportunity for our core business in treating sleep-disordered breathing and for our growing portfolio of respiratory care and cardiology solutions. This acquisition continues ResMed's emerging market strategy of growing our distribution to bring market-leading sleep-disordered breathing and respiratory care solutions to places where they're needed most." According to the Company, Unimedis will continue to serve the entire Czech Republic and Slovakia under the leadership of Ondrej Kalas, who will remain with ResMed as Country Manager for the Czech Republic and Slovakia. The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/bd44_RMD
--
Wright Medical Group Inc. Research Report
Wright Medical Group Inc. (Wright Medical Group) posted on its events calendar that the Company will conduct its Q4 2013 earnings conference call on February 24, 2014. According to the Company, the said event is slated to start at 3:30 p.m. CT. The Full Research Report on Wright Medical Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/1782_WMGI
--
Chemed Corp. Research Report
On December 4, 2013, Chemed Corp. (Chemed) announced that it will make a presentation at the Oppenheimer 24th Annual Healthcare Conference on Tuesday, December 10, 2013, at approximately 1:00 p.m. ET at the Crowne Plaza Hotel in New York City. According to the Company, interested parties can access the live webcast of the presentation via the Investor Relation section of Chemed's website. The Full Research Report on Chemed Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/4c0d_CHE
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article